archive-org.com » ORG » H » HUANGE.ORG

Total: 245

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Recent posts | Huange Foundation
    node new comments inc on line 99 strict warning Declaration of views handler argument init should be compatible with views handler init view options in home csgmyrs public html web6 sites all modules views handlers views handler argument inc on line 745 strict warning Declaration of views handler filter options validate should be compatible with views handler options validate form form state in home csgmyrs public html web6 sites all modules views handlers views handler filter inc on line 589 strict warning Declaration of views handler filter options submit should be compatible with views handler options submit form form state in home csgmyrs public html web6 sites all modules views handlers views handler filter inc on line 589 strict warning Declaration of views handler filter boolean operator value validate should be compatible with views handler filter value validate form form state in home csgmyrs public html web6 sites all modules views handlers views handler filter boolean operator inc on line 149 Type Title Author Replies Last Post Page Huange Foundation Inc admin 0 01 29 2011 09 59 Page 黄义基金会 admin 0 01 29 2011 10 35 Page Welcome to Huange Foundation admin 0 01 29 2011 10 55 Page 欢迎访问黄义基金 admin 0 01 29 2011 10 58 Page 歡迎訪問黃義基金 admin 0 01 29 2011 11 07 Poll Which language do you speak admin 0 01 29 2011 11 25 Poll 选择你说的语言 admin 0 01 29 2011 11 33 Poll 選擇你的語言 admin 1 01 29 2011 11 36 Forum topic 测试讨论 admin 0 01 29 2011 12 16 Forum topic 測試討論 admin 0 01 29 2011 12 17 Page 黃義基金會 admin 0 01 29 2011 12 22 Webform Patient Registry admin 0 01 29 2011 15 36 Webform 患者注册 admin 0 01 29 2011 16 23 Webform 患者注冊 admin 0

    Original URL path: http://huange.org/web6/tracker?order=last_comment_timestamp&sort=asc (2016-02-16)
    Open archived version from archive

  • Stem-Cell Treatment for Blindness Advances in Human Trials | Huange Foundation
    the leading cause of vision loss among people 65 and older according to the Centers for Disease Control and Prevention As the journal The Lancet reports the stem cell treatment is safe although a full report of the results from the early safety focused testing has yet to be published The treatment is based on retinal pigment epithelium RPE cells that have been grown from embryonic stem cells A surgeon injects 150 microliters of RPE cells the equivalent of three raindrops under a patient s retina which is temporarily detached for the procedure RPE cells support the retina s photoreceptors which are the cells that detect incoming light and pass theinformation on to the brain So far one patient s results in particular were encouraging they recovered full vision after being judged legally blind We continue to be encouraged by the progress we see in our ongoing clinical investigations Gary Rabin chairman andCEO of ACT commented in a press release Our plan is still to publish additional results from the clinical investigations when we have a significant aggregation of data The company s more advanced trials will have dozens of participants compared to the 12 from the early stage trials

    Original URL path: http://huange.org/web6/node/149 (2016-02-16)
    Open archived version from archive

  • Gene Therapy Treats Usher Syndrome Patients | Huange Foundation
    Fighting Blindness and Oxford BioMedica announced that the first Usher Syndrome patient is about to be treated at Casey Eye Institute OHSU with Oxford s UshStat gene therapy treatment The trial is aimed at patients with Usher Syndrome Type 1B a form or retinitis pigmentosa that leads to blindness and hearing loss There is currently no treatment for this disease Based on laboratory pre clinical studies the researchers believe that

    Original URL path: http://huange.org/web6/node/142 (2016-02-16)
    Open archived version from archive

  • QLT Receives Fast Track Designations for QLT091001 to Treat Both Leber Congenital Amaurosis and Retinitis Pigmentosa | Huange Foundation
    Retinitis Pigmentosa Wed 09 14 2011 08 05 sfan Check out this news VANCOUVER British Columbia Sep 14 2011 GlobeNewswire via COMTEX QLT Inc QLTI 4 60 CA QLT 3 90 today announced the Company s oral synthetic retinoid for retinal diseases QLT091001 has been granted two Fast Track designations by the U S Food and Drug Administration FDA for the treatment of Leber Congenital Amaurosis LCA due to inherited

    Original URL path: http://huange.org/web6/node/64 (2016-02-16)
    Open archived version from archive

  • Genable Technologies – a gene based medicines platform | Huange Foundation
    diseases based on the pioneering work of Professor Jane Farrar Dr Paul Kenna Professor Peter Humphries Genable utilizes well established clinically safe effective AAV vectors to obtain expression of RNA interference RNAi molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein The combination of suppression and replacement S R overcomes the significant hurdle in dominant disease of mutation variability by eliminating the need to target specific mutations in a wide range of disorders Genable s technology is protected by a broad suite of granted patents and patent applications in the USA EU and worldwide Genable s first gene medicine GT038 is for treatment of patients with rhodopsin RHO linked autosomal dominant retinitis pigmentosa adRP a debilitating form of inherited blindness resulting from a diverse array of mutations in the RHO gene This sub type of adRP affects approximately 1 in 30 000 people and represents an already identified and potentially treatable population of around 30 000 patients in the US and Europe Whilst we estimate the market opportunity for GT038 in this sub type of

    Original URL path: http://huange.org/web6/node/63 (2016-02-16)
    Open archived version from archive

  • Gene Therapy Successful in Usher Syndrome Type 2D Model | Huange Foundation
    treatment into a clinical trial Usher syndrome is an inherited condition that causes defects in the function of cilia tiny hair like structures that act like a transportation system for proteins and biochemicals essential to the proper functioning of photoreceptors and cells of the inner ear In people with USH 2D a genetic defect leads to dysfunction of the cilia and ultimately vision and hearing loss Led by Dr Jun Yang the Foundation funded research team developed a safe manmade virus to deliver copies of normal USH 2D genes to the photoreceptors of the affected mice The treatment was injected under the retina where it was absorbed by the photoreceptors Tests revealed that copies of the therapeutic USH 2D gene reached photoreceptors and restored function of the cilia The virus used for therapy delivery an adeno associated virus or AAV is similar to AAVs used in other gene therapy lab studies and clinical trials One example is the series of landmark clinical trials that have restored some vision in more than 40 children and young adults with the early onset retinal disease known as Leber congenital amaurosis Dr Yang said that while the treatment restored ciliary function retinal degeneration and

    Original URL path: http://huange.org/web6/node/62 (2016-02-16)
    Open archived version from archive

  • 第16届视网膜国际大会有关RP的文章 | 黄 义 基 金 会
    比如皮肤细胞 可以在试管内 体外 诱导生成为可变为视神经细胞的干细胞 这项重大发现可以使患有视网膜疾病的患者将体内成熟的细胞转换为多潜能细胞 这些多潜能细胞可以行使正常视神经细胞的功能 每年的视觉与眼年会中 都会有一些话题引起人们的注意 干细胞研究以及干细胞治疗方法在此次年会中引起了广泛的关注 多家实验室已经制定出了将胚胎干细胞 ES 及诱导性多潜能干细胞 iPS 转变为视网膜细胞的计划 并且通过动物实验发现 从上述两种干细胞转换成的视网膜细胞可以变为视网膜的一部分 在美国 基于干细胞技术的治疗产品都要通过美国食品 管理局的生物制品评价及研究中心审核 审核中要考虑的因素包括干细胞移植物的生命力 如何将干细胞输送到患者体内 干细胞进一步分化增殖成其他类型的细胞及癌变的可能性 以及细胞在体内的融合性等等 干细胞治疗是一门新兴的学科 因此在用于人体之前要对其安全性及效能进行完全彻底的研究 T A Reh K Wallace D O Clegg M Friedlander D W Fink 法国RP患者的EYS基因突变 研究人员通过对法国RP患者的研究发现 在法国并且可能在世界其他地方 EYS基因突变是导致RP的重要原因 EYS基因是人眼中已知的最大的基因 范围超过2兆位 在对超过200个散发及常染色体隐性RP患者的研究中 研究人员发现超过37例可能的EYS基因突变 一些患者只有单独突变 而其他患者有多种突变 这些患者中大多数都有RP的典型症状 比如中心视力受损较晚 在对上述患者的研究中发现EYS基因突变非常普遍 这表明在其他RP患者中 EYS基因突变可能也会扮演重要的角色 睫状营养因子疗法增加了黄斑厚度 王涛及她的同事在2010的年会上阐述了她们研究的新发现 她们的眼内移植封装细胞技术 ECT 的移植体内装有经过基因修改可以潜入眼内的睫状营养因子 CNTF 移植体植入眼内后可以持续释放营养因子 这样会防止患有视网膜退化疾病的患者的感光细胞凋亡 睫状营养因子 CNTF 已经在患有RP 的患者上进行了实验 实验结果表明其具有积极的生物效用 睫状营养因子 CNTF 的一个效用就是大幅度的增加了黄斑及感光细胞层的厚度 而增加的幅度与CNTF的用量有关

    Original URL path: http://huange.org/web6/zh-hans/node/57 (2016-02-16)
    Open archived version from archive

  • 中南大学湘雅二医院干细胞重大突破 | 黄 义 基 金 会
    93 语言 简体中文 繁體中文 English 首页 论坛 成员讨论区 聊聊最新科研突破 中南大学湘雅二医院干细胞重大突破 星期六 08 27 2011 11 13 sbfan 中南大学湘雅二医院干细胞重大突破 http www rpsun cn rpbbs thread 10752 1 2 html 中南大学湘雅二医院 美国路易斯维尔大学James Graham Brown癌症中心等处的研究人员发现利用干细胞可以修复受损视网膜组织 他们介绍了如何将干细胞分离并在猪之间进行移植 克服了研究的一个重要障碍 这一研究成果公布在 Stem Cells 杂志上 文章的通讯作者是路易斯维尔大学Douglas C Dean教授 第一作者是中南大学湘雅二医院Liang Zhou 近期Nature杂志上发表文章 报道了首次把哺乳动物的干细胞培育成为胚胎阶段的眼睛的重要研究成果 这项研究从多能性干细胞 即最终可发育成为机体内几乎每一种专门细胞的起始细胞 入手 利用新的实验室技术 设法刺激老鼠胚胎干细胞的转变 使之形成所谓的 视杯 即最后发育成为眼睛视网膜的层状三维结构体 但是这种方法毕竟耗时较长 花销较大 在 Stem Cells 这篇文章中 研究人员则将目光转移到了猪身上 因为和人类一样 猪眼睛含有一种占优势地位的锥状中心视觉条带 使其在解剖学与生理学上实现更好的匹配 过去对猪模型的研究一直受到阻碍 因为人们尚未从猪身上分离出用于此类移植的诱导性多能干细胞 iPSCs 同时 它们与宿主光感受细胞的相容性也尚未得到证实 而这项研究从猪皮肤成纤维细胞中收集了诱导性多能干细胞 研究表明

    Original URL path: http://huange.org/web6/zh-hans/node/56 (2016-02-16)
    Open archived version from archive



  •